<DOC>
	<DOC>NCT00046254</DOC>
	<brief_summary>The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.</brief_summary>
	<brief_title>Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture</brief_title>
	<detailed_description />
	<mesh_term>Fractures, Bone</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Osteoporotic Fractures</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Male or female ages 50 years or older Must have a recent hip fracture repair in the past 90 days Must be able to walk with or without assistive device (for example, using a walker) prior to the hip fracture Current bisphosphonate users such as aredia (pamidronate), didronel (etidronate), fosamax (alendronate), actonel (residronate), skelid (tiludronate) Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>hip fracture</keyword>
	<keyword>recurrent fracture</keyword>
	<keyword>fracture</keyword>
	<keyword>bone loss</keyword>
	<keyword>bisphosphonate</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>geriatrics</keyword>
	<keyword>rehabilitation</keyword>
	<keyword>elderly</keyword>
	<keyword>nursing home</keyword>
	<keyword>orthopedic</keyword>
</DOC>